Sequencing Targeted Therapies With High-Dose Interleukin 2 Immunotherapy in Metastatic RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Impact of Sequencing Targeted Therapies With High-Dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-Going Observational IL-2 Clinical Trial: PROCLAIM(SM)
Clin Genitourin Cancer 2016 Oct 28;[EPub Ahead of Print], JI Clark, MK Wong, HL Kaufman, GA Daniels, MA Morse, DF McDermott, SS Agarwala, LD Lewis, JH Stewart, U Vaishampayan, B Curti, R Gonzalez, J Lutzky, V Rudraptna, LD Cranmer, JM Jeter, RJ Hauke, G Miletello, MM Milhem, A Amin, JM Richart, M Fishman, S Hallmeyer, SP Patel, P Van Veldhuizen, N Agarwal, B Taback, JS Treisman, MS Ernstoff, JC Perritt, H Hua, TB Rao, JP Dutcher, S AungFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.